DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

Information source: Charite University, Berlin, Germany
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Moderate to Severe Active Axial Spondyloarthritis

Intervention: Etanercept 25mg (Drug); Sulfasalazine (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Joachim Sieper, MD, Principal Investigator, Affiliation: Charite, Campus Benjamin-Franklin, Rheumatology, Berlin, Germany

Overall contact:
Joachim Sieper, MD, Phone: 0049-30-8445, Ext: 4535, Email: joachim.sieper@charite.de

Summary

Efficacy - To assess efficacy of etanercept versus sulfasalazine when added to NSAIDs in

patients with moderate to severe active early axial spondyloarthritis duration of ongoing axial symptoms of less than 5 years. Primary outcome is change of active inflammatory lesions in sacroiliac joints and spine as detected by MRI at 12 months. Secondary outcome parameters are clinical and laboratory efficacy parameters and MRI changes at 6 months and 2 years. Comparisons will be made within the two treatment arms and compared to baseline. At the 1 year extension phase comparisons will be also made between year 1 and year 2. At the end of the extended study a pelvic x-ray is planned.

Clinical Details

Official title: Randomized Controlled 12 Months Trial With Etanercept (Enbrel ģ) vs. Sulfasalazine in Early Axial Spondyloarthritis With Focus on Improvement of Acute Inflammatory Lesions as Detected by MRI. Amendment 4: 1-Year Extension of Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Primary outcome: Reduction of active inflammatory lesions in MRI at 12 months.

Secondary outcome: Secondary outcome: ASAS 20%, 40%, 70% response, ASAS criteria for partial remission· BASDAI 20%, 50%, 70% improvement · BASFI ·

Detailed description: Randomized controlled study with two treatment arms (Phase II), 1 year open extension

Efficacy - To assess efficacy of etanercept vs. sulfasalazine when added to NSAIDs in

patients with moderate to severe active early axial spondyloarthritis duration of ongoing axial symptoms of less than 5 years. Primary outcome is change of active inflammatory lesions in sacroiliac joints and spine as detected by MRI at 12 months. Secondary outcome parameters are clinical and laboratory efficacy parameters and MRI changes at 6 months and 2 years. Comparisons will be made within the two treatment arms and compared to baseline. At the 1 year extension phase comparisons will be also made between year 1 and year 2. At the end of the extended study a pelvic x-ray is planned. For etanercept group: To assess whether etanercept will show sustained long term response over 1 more year. To assess whether etanercept will slow or stop progression as shown by MRI. For sulfasalazine group: to assess whether etanercept will show long term response over 1 year. To assess whether etanercept will slow or stop progression as shown by MRI. For all patients who are in remission the duration of remission will be assessed for a maximum of one year. In case of a flare of the disease these patients will be (re-) treated with etanercept and efficacy will be assessed.

Safety - To study the long-term safety of etanercept in patients with moderate to severe

active early axial spondyloarthritis compared to patients treated with sulfasalazine over a period of one year.

Patients will be treated for 1 year either with etanercept 2x25mg per week subcutaneously or with sulfasalazine 2g/ day given orally. Following screening and baseline evaluations, patients will be assessed at week 2, 4, 6, 8, 10, 12, 24, 36 and 48. Efficacy and safety measurements will be recorded throughout the entire study. The study will be followed by a 60 weeks follow-up phase after week 48 (end of treatment phase). In case of flare they will be (re-)treated with etanercept for further 60 weeks (until week 108). All patients from the former etanercept group who are not in remission will continue to be treated with etanercept for 60 weeks (weeks 60, 72, 84, 96, 108). All patients from the former sulfasalazine group who are not in remission will be switched to etanercept for 60 weeks (at weeks 50, 54, 60, 72, 84, 96, 108).

Treatment arms: Arm 1: 40 patients receive etanercept 2x25 mg weekly subcutaneous injectionArm 2: 40 patients receive sulfasalazine up to 2 g/day (up to 3 g/ per day)

Duration of the study: 12 months. For patients in remission a 12 months follow up period will be enclosed. Treatment will be continued for patients in case of flare or in patients who did not achieve remission for 60 weeks. The study is planned start at September 2005. Patients will be recruited over a 12 months period. Altogether the duration of the study is up to 51 months. All patients who are willing to participate in the extension will be treated for another 60 weeks.

Patient Population: Only active axial SpA patients with a disease duration (measured from time of ongoing spinal symptoms) of less than 5 years will be included. This implies that patients with both radiological evidence of sacroiliitis (fulfilling the modified New York criteria for AS) and without radiological evidence of sacroiliitis (see inclusion criteria) will be included.

Efficacy Variables: Primary endpoint: · Reduction of active inflammatory lesions in MRI at 12 monthsSecondary endpoints:

- ASAS 20%, 40%, 70% response, ASAS criteria for partial remission· BASDAI 20%, 50%, 70%

improvement · BASFI · Mobility examinations: BASMI, Chest Wall Expansion· disease controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6)*· CRP, ESR· Quality

of Life: SF-36· Numeric Rating Scale (NRS) - physicians global, patients global,

general pain, nocturnal pain · Enthesitis index (Maastricht scale)· swollen joint count· EQ-5D· Socio-economic questionnaire· Chronic changes in MRI at 6, 12 months and 108 weeks· Reduction of active inflammatory lesions in MRI at 6 months and chronic lesions at 6 and 12 months and 108 weeks

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients 18 - 50 years of age who have moderate to severe active axial

spondyloarthritis.

- Diagnosis made by :Chronic low back pain (duration > 3 months, onset < 45 years of

age)plus 3 out of the 6 following criteria if imaging is positive or 4 out of the following 6 criteria if imaging is negative ·

- Inflammatory back pain:

- Good or very good response to NSAIDs

- One or more of the following extraspinal manifestations: uveitis, peripheral

arthritis, enthesitis, HLA-B27 positive

- Positive imaging: MRI showing acute inflammatory lesions in spine or SIJ (in the

past) or bilateral sacroiliitis grade 2-4 or unilateral sacroiliitis grade 3-4 in x-ray not older than 12 months

- Positive family history for SpA

- MRI at screening showing acute inflammatory lesions in SIJ or spine

- Active disease is defined as:

- a BASDAI score of >=4

- back pain score (BASDAI question 2) of >= 4 despite concurrent NSAID therapy, or

intolerance to NSAIDs.

- Other inclusion criteria include, if on prednisone:

- <7. 5 mg per day

- stable for 4 weeks prior to baseline

- Women of child bearing potential must have a negative pregnancy test at study

baseline and use an adequate, effective method of contraception for a duration of 6 months after stop of etanercept therapy. Sexual active men must use an accepted method of contraception for a duration of 6 months after stop of etanercept therapy.

- Reading a normal chest/lung x-ray which should have been performed within the last 12

weeks before inclusion

- Able to self-administer injectable drug supplies or have a caregiver who will do so.

- Able to store injectable test article at 2¬į to 8¬į C.

Exclusion Criteria:

- Disease duration of longer than 5 years

- History of active tuberculosis (TB), histoplasmosis or listeriosis.

- History of positive HIV status, known hepatitis B or C

- History of malignancy other than carcinoma in situ of the cervix or adequately

treated non-metastatic squamous or basal cell skin carcinoma.

- Antibiotic treatment within 3 weeks prior to screening.

- Previous treatment with TNF-alpha blockers

- Treatment with sulasalazine in the last 6 months before participation in the clinical

trial

- severe internal medical diseases such as severe cardiac, hepatic, gastrointestinal,

neurological, psychiatric diseases

Locations and Contacts

Joachim Sieper, MD, Phone: 0049-30-8445, Ext: 4535, Email: joachim.sieper@charite.de

Charité Campus Mitte, Rheumatology, Berlin 10117, Germany; Recruiting
Gerd-Ruediger Burmester, MD, Phone: 0049-30-450513, Ext: 025, Email: gerd.burmester@charite.de

Klinikum Buch, Berlin 13125, Germany; Recruiting
Andreas Krause, MD, Phone: 0049-30-94792, Ext: 380, Email: a.krause@immanuel.de

Immanuel Krankenhaus, Berlin 14109, Germany; Recruiting
Andreas Krause, MD, Phone: 0049-30-80505-, Ext: 293, Email: a.krause@immanuel.de

Praxis Zinke, Berlin 13055, Germany; Recruiting
Silke Zinke, MD, Phone: 0049-30-98695, Ext: 231, Email: dr.silke.zinke@t-online.de

Waldkrankenhaus, Berlin 13589, Germany; Recruiting
Ulrich Prothmann, MD, Phone: 0049-30-3702-, Ext: 1302, Email: u.prothmann@waldkrankenhaus.com

Schlossparkklinik, Rheumatology, Berlin 14059, Germany; Recruiting
Rieke Alten, MD, Phone: 0049-303264-, Ext: 1333, Email: rieke.alten@schlosspark-klinik.de

Praxis Mielke, Berlin 12627, Germany; Recruiting
Mielke, MD, Phone: 0049-30-994, Ext: 21 22

Praxis Klopsch, Neubrandenburg 17033, Germany; Recruiting
Thilo Klopsch, MD, Phone: 0049-395- 775, Ext: 43 24, Email: dr.thilo.klopsch@t-online.de

Praxis Bohl-B√ľhler, Potsdam 14469, Germany; Recruiting
Martin Bohl-B√ľhler, MD, Phone: 0049-331- 647352, Ext: 1, Email: info@Rheumahaus.de

Additional Information

Starting date: November 2005
Last updated: February 12, 2009

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014